WO2020131147A1 - Topical compositions - Google Patents

Topical compositions Download PDF

Info

Publication number
WO2020131147A1
WO2020131147A1 PCT/US2019/023203 US2019023203W WO2020131147A1 WO 2020131147 A1 WO2020131147 A1 WO 2020131147A1 US 2019023203 W US2019023203 W US 2019023203W WO 2020131147 A1 WO2020131147 A1 WO 2020131147A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
weight
composition
carbon atoms
component
Prior art date
Application number
PCT/US2019/023203
Other languages
French (fr)
Inventor
Perry Forrester
Joshua Scott
Original Assignee
Marlinz Pharma, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/225,980 external-priority patent/US10543276B2/en
Application filed by Marlinz Pharma, LLC filed Critical Marlinz Pharma, LLC
Priority to CA3122016A priority Critical patent/CA3122016A1/en
Priority to JP2021536333A priority patent/JP2022518357A/en
Priority to AU2019405915A priority patent/AU2019405915A1/en
Priority to EP19898484.1A priority patent/EP3897604A4/en
Priority to SG11202105755PA priority patent/SG11202105755PA/en
Priority to KR1020217022200A priority patent/KR20210107043A/en
Priority to MX2021006810A priority patent/MX2021006810A/en
Publication of WO2020131147A1 publication Critical patent/WO2020131147A1/en
Priority to IL284072A priority patent/IL284072A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Definitions

  • the present invention relates to topical compositions for skin tissue including nails and, in particular, to liquid carriers/vehicles for pharmacologically active components forming the topical coposition.
  • compositions for topical application to the skin heavily rely on the penetrating ability of the composition for maximum efficacy.
  • treatments of fungal infections of the toe nail, or toe nail discoloration due to other underlying factors are largely dependent on the ability of the active agent, an antifungal to penetrate the skin surrounding the nail as well as the nail itself.
  • nails are actually produced by living skin cells in the toe or finger.
  • ingredients used in cosmetic applications can hydrate, thin, and normalize the color of nails and skin. Rehydrating a fungal nail that is dehydrated and dried out can increase porosity of the cells in the nail matrix making it easier for penetration of agents needed to treat the nail, e.g., for fungus.
  • Jublia® antifungal composition for the treatment of nail disorders such onychomycosis or psoriasis affecting the nails, a widely used prescription antifungal is sold under the trademark Jublia®.
  • the composition of the Jublia® antifungal composition uses a vehicle in which the active ingredient is dissolved, which preferably comprises a linear or branched aliphatic lower alcohol, such as ethanol, methanol, propanol, or isopropanol.
  • a linear or branched aliphatic lower alcohol such as ethanol, methanol, propanol, or isopropanol.
  • U.S. Patent 10,05,444 (‘444 Patent), incorporated herein by reference for all purposes, covers the Jublia® antifungal composition.
  • The‘444 Patent encompasses and is focused on the fact that the composition claimed therein meets a significant need for a pharmaceutical composition that provides for enhanced penetration of a pharmaceutical agent contained within the composition into, under, around, and through a nail into the nail bed.
  • the composition of the‘444 Patent also relies on a surfactant to reduce surface tension and a volatile silicone to act as a wetting agent.
  • the teachings of the‘444 Patent highlight the fact that penetration is quite important in successfully treating skin disorders, e.g., fungal infections, of the nails and surrounding tissue.
  • the present invention relates to an antifungal composition for application to the toe nail and adjoining tissue.
  • the present invention relates to a pharmaceutically active composition for the treatment of fungal infections on and surrounding the toe nail.
  • the present invention relates to a composition
  • a composition comprising a carrier and an effective amount of a pharmaceutically active antifungal component wherein the antifungal component is uniformly dispersible in a carrier.
  • the present invention relates to a carrier or vehicle for use in the topical application of dermatologically active ingredients.
  • the present invention relates to a carrier for use in topical application of dermatologically active ingredients which exhibits good penetrating ability.
  • Fig. 1 shows the penetrating ability of the compositions of the present invention as compared to a widely used commercial prior art product.
  • the terms“nail” or“nails” means one or more of the toe nails and/or finger nails of an animal, particularly humans.
  • the present invention comprises a liquid carrier or vehicle for dermatologically active ingredients (DAIs), e.g., antifungals or cosmetic components, to form a dermatologically active composition (DAC).
  • DAIs dermatologically active ingredients
  • DAC dermatologically active composition
  • the liquid carrier or vehicle comprising the present invention contains dimethyl isosorbide, undecylenic acid, a carboxylic acid component other than undecylenic acid, a monohydric alcohol having from 2 to 4 carbon atoms, and a urea based component.
  • the carrier will contain:
  • urea-based component is urea itself
  • a suitable urea-based component can comprise urea peroxide or carbamide peroxide.
  • Urea-based components act as nail penetrators and/or softeners. Further, these urea-based components serve a cosmetic function in that they improve the visual appearance of the nail by hydrating and thinning hyperkeratotic nails, thereby providing an incentive for the user to be diligent in applying the DAC.
  • the carrier of the present invention comprises a monohydric alcohol containing 2 to 4 carbon atoms.
  • the monohydric alcohol can be ethanol, propanol, isopropanol, etc., isopropanol being preferred.
  • the carrier can contain up to about 7% water.
  • the carrier of the present invention also contains a carboxylic acid component other than undecylenic acid.
  • the carboxylic acid component comprises a C1 to C10 organic acid which can be alone and/or in an aqueous solution.
  • C1 -C10 carboxylic acids suitable for use in the carrier of the present invention include saturated and/or unsaturated, linear and/or branched, aliphatic, mono-, di-, carboxylic acids, alkylaryl or aromatic dicarboxylic acids, oxy- and hydroxyl- carboxylic acids (e.g., alpha- hydroxy acids).
  • Preferred carboxylic acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, capyric acid, capric acid, sorbic acid, oxalic acid, hydroxybutyric acid, hydroxypropionic acids, lactic acid, glycolic acid, citric acid, malic acid, tartartic acid, malonic acid, fumaric acid, succinic acid, glutaric acid, apidic acid, pimelic acid, oxalacetic acid, phthalic acid, tartronic acid, pyruvic acid, and mixtures thereof.
  • An especially preferred carboxylic acid is lactic acid.
  • undecylenic acid (undec-10-enoic acid), an unsaturated fatty acid. While not wanting to be bound by any particular theory, it is believed undecylenic acid acts as a linking agent which brings certain components of the carrier together to enhance penetration. It is also believed that undecylenic acid can act as a biocide/antimicrobial to some extent and thereby enhance the stability of the carrier of the present invention. Further, when the carrier is used in forming a DAC employing an antifungal as the active ingredient, the undecylenic acid has the additional benefit that, in and of itself, in certain amounts it possesses antifungal properties thereby enhancing the efficacy of the DAC. Undecylenic acid also reduces the surface tension of and emulsifies other agents present in the carrier.
  • DMI dimethyl isosorbide
  • a useful component which can be used in the carrier of the present invention can also include a diol containing from about 2 to about 4 carbon atoms.
  • suitable diols include ethylene glycol, propylene glycol, etc.
  • a preferred diol is propylene glycol. If used, the diol will generally be present in an amount of from about 4 to about 15% by weight, preferably from about 4 to about 10% by weight.
  • Another useful component which can be used in the carrier comprises about 10% by weight of a carboxylic acid ester having the formula:
  • Ri comprises 1 to 3 carbon atoms
  • R2 comprises 2 to 4 carbon atoms.
  • Yet another useful component which may be used in the carrier comprises from about 2 to about 10% by weight of a fatty acid ester having the formula
  • Ri comprises 1 to 3 carbon atoms
  • R3 comprises 10 to 22 carbon atoms.
  • adjunct components mentioned above i.e. , diols and esters, including the fatty acid esters, can be useful in certain applications to make the DACs more pleasing in smell and/or for ease in application. However, they are not considered to be critical components of the carrier and/or the DACs comprising the carrier.
  • a feature of the carrier of the present invention is that a wide variety of DAI’s are dispersible in the carrier.
  • the term “dispersible,” “dispersion,” or variants thereof is intended to mean and include a solution, an emulsion, a suspension, or a slurry to the extent the slurry can be formed into a uniform dispersion of particles / carrier with sufficient agitation and remain in that uniform state for a period of time sufficient for the carrier and its dispersed ingredient(s) to be uniformly applied to a skin surface, e.g., the nail and surrounding tissue.
  • the carrier of the present invention is a liquid vehicle in which the DAI can be dissolved, suspended, dispersed, or emulsified.
  • the DAC of the present invention may form a single phase, e.g., a solution, or separate phases, e.g., a slurry, emulsion, suspension, or the like.
  • the slurry will be one which upon sufficient agitation can be formed into a uniform dispersion or suspension for a period of time to allow the DAC to be applied to the desired skin or nail area, the DAI being delivered to the affected skin area in a generally uniform fashion.
  • the DAC of the present invention may be prepared in a number of forms including creams, milks, solutions, tinctures, liniments, liquids, sprays, suspensions, gels, or lotions.
  • the carrier composition of the present invention can be used to “bleach” and/or remove discoloration from nails which may have been caused by several well known underlying diseases.
  • the DAC from a cosmetic perspective, can be the carrier alone or have incorporated the DAIs such as skin softeners, emollients, etc.
  • DAI comprising an antifungal
  • antifungal any antifungal can be employed.
  • the following well known, widely used antifungals for skin tissue, including nails includes, without limitation:
  • -Azoles including efinaconazole, clotrimazole, miconazole nitrate, ketoconazole, econazole, bifonazole, oxiconazole, tioconazole, sertaconazole, luliconazole, eberconazole, sulconazole, fenticonazole, fluconazole, preferably efinaconazole, clotrimazole, or miconazole nitrate.
  • -Allylamines including preferably, terbinafine, naftifine hydrochloride, butenafine hydrochloride,
  • -Morpholines including preferably amorolfine hydrochloride
  • Hydroxyquinolines including preferably clioquinol
  • -Oxaboroles including preferably tavaborole
  • -Thiocarbamates including preferably tolfnaftate
  • the antifungal is selected from thiocarbamates, azoles, and allylamines, even more preferably tolnaftate, clotrimazole, and terbinafine, the most preferred antifungal being tolnaftate.
  • antifungals when antifungals comprise the DAI, they will be present in an effective amount, wherein an effective amount means an amount necessary to affect a curative change in the fungus or other abnormality being treated. In this regard, it is well within the scope of the skilled artisan to determine what constitutes an effective amount.
  • the literature is replete with compositions containing antifungals and the relative amounts used in such compositions. Accordingly, the skilled artisan would not have to engage in undue experimentation to determine what amount of antifungal should be used in the DACs of the present invention.
  • the antifungals when the antifungals comprise the DAI, they will comprise from greater than 0 to about 15% by weight or greater of the DAC.
  • the antifungal component was mixed with dimethyl isosorbide, forming
  • Mixture A B) Urea, undecylenic acid, lactic acid, and IPA were mixed together forming Mixture B.
  • compositions of the various DACs prepared are shown in Table 1.
  • the penetration test was conducted using a substrate comprising polyurethane foam blocks marketed by Pacific Research Laboratories under the designation“Block 10 PCF” and commonly used for biomechanical testing.
  • the faces of two blocks of the substrate were positioned between platens, the assembly of platens and substrate blocks being compressed together using the same and constant compression for each test..
  • Each of the samples was dyed with fluorescein to improve visibility of the liquid.
  • Two drops of each sample were applied at the top on the seam between the compressed substrate blocks.
  • the samples were allowed to sit for 20 seconds, then the excess liquid was dabbed away.
  • the samples were then allowed to dry for 2 minutes, after which the blocks were separated.
  • the amount of penetration of the sample through the substrate was observed.
  • Fig. 1 the borders of the penetration of the samples have been traced with a marker for ease of viewing.
  • all of the compositions of the present invention penetrated further than the Jublia® composition.
  • the carrier compositions of the present invention are effective at dispersing, as that term is defined above, a wide variety of antifungals from varied classes of antifungals, all of which are known to have antifungal activity.
  • the DACs of the present invention wherein the DAIs are antifungals show better penetrating ability than the Jublia® formulation. This is significant, as noted above, since in the Jublia® composition in order to enhance penetration, the compositions require, in addition to an alcohol, a surfactant, and a volatile silicone wetting agent.
  • the preferred embodiment of the present composition incorporates urea and lactic acid which collectively thin thickened nails, enhance nail hydration and diminish discoloration.

Abstract

A pharmaceutically active composition containing an effective amount of a pharmacologically active ingredient such as an antifungal and a carrier. The carrier comprises dimethyl isosorbide, undecylenic acid, a lower carboxylic acid other than undecylenic acid, a monohydric alcohol having from 2 to 4 carbon atoms, and urea.

Description

TOPICAL COMPOSITIONS
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of U.S. Application No. 15/671 ,719 filed on August 8, 2017, which in turn claims priority to US 62/,372, 132, the disclosures of which are incorporated herein by reference for all purposes.
FIELD OF THE INVENTION
The present invention relates to topical compositions for skin tissue including nails and, in particular, to liquid carriers/vehicles for pharmacologically active components forming the topical coposition.
BACKGROUND OF THE INVENTION
Compositions for topical application to the skin, whether purely cosmetic, pharmaceutical, or mixtures thereof, heavily rely on the penetrating ability of the composition for maximum efficacy. For example, treatments of fungal infections of the toe nail, or toe nail discoloration due to other underlying factors, are largely dependent on the ability of the active agent, an antifungal to penetrate the skin surrounding the nail as well as the nail itself. In this regard nails are actually produced by living skin cells in the toe or finger.
Additionally certain ingredients used in cosmetic applications can hydrate, thin, and normalize the color of nails and skin. Rehydrating a fungal nail that is dehydrated and dried out can increase porosity of the cells in the nail matrix making it easier for penetration of agents needed to treat the nail, e.g., for fungus.
With particular respect, and by way of example only, for the treatment of nail disorders such onychomycosis or psoriasis affecting the nails, a widely used prescription antifungal is sold under the trademark Jublia®. The composition of the Jublia® antifungal composition, uses a vehicle in which the active ingredient is dissolved, which preferably comprises a linear or branched aliphatic lower alcohol, such as ethanol, methanol, propanol, or isopropanol. U.S. Patent 10,05,444 (‘444 Patent), incorporated herein by reference for all purposes, covers the Jublia® antifungal composition. The‘444 Patent encompasses and is focused on the fact that the composition claimed therein meets a significant need for a pharmaceutical composition that provides for enhanced penetration of a pharmaceutical agent contained within the composition into, under, around, and through a nail into the nail bed. To accomplish enhanced penetration, and in addition to the lower alcohol, the composition of the‘444 Patent also relies on a surfactant to reduce surface tension and a volatile silicone to act as a wetting agent. In any event, the teachings of the‘444 Patent highlight the fact that penetration is quite important in successfully treating skin disorders, e.g., fungal infections, of the nails and surrounding tissue. SUMMARY OF THE INVENTION
In one aspect, the present invention relates to an antifungal composition for application to the toe nail and adjoining tissue.
In another aspect, the present invention relates to a pharmaceutically active composition for the treatment of fungal infections on and surrounding the toe nail.
In still a further aspect, the present invention relates to a composition comprising a carrier and an effective amount of a pharmaceutically active antifungal component wherein the antifungal component is uniformly dispersible in a carrier.
In yet another aspect, the present invention relates to a carrier or vehicle for use in the topical application of dermatologically active ingredients.
In still another aspect, the present invention relates to a carrier for use in topical application of dermatologically active ingredients which exhibits good penetrating ability.
These and further features and advantages of the present invention will become apparent from the following detailed description, wherein reference is made to the figures in the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the penetrating ability of the compositions of the present invention as compared to a widely used commercial prior art product.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
As used herein, the terms“nail” or“nails” means one or more of the toe nails and/or finger nails of an animal, particularly humans.
Broadly, the present invention comprises a liquid carrier or vehicle for dermatologically active ingredients (DAIs), e.g., antifungals or cosmetic components, to form a dermatologically active composition (DAC). In its basic form, the liquid carrier or vehicle comprising the present invention contains dimethyl isosorbide, undecylenic acid, a carboxylic acid component other than undecylenic acid, a monohydric alcohol having from 2 to 4 carbon atoms, and a urea based component.
In general, the carrier will contain:
-from greater than 0 to about 40% by weight, preferably from greater than 0 to about 25% by weight, more preferably from about 1 % to about 20% by weight, of dimethyl isosorbide
- from about 1 % to about 40% by weight, preferably from about 5% to about 35% by weight of undecylenic acid
-from greater than 0 to about 30% by weight, preferably from greater than 0 to about 25% by weight, more preferably from about 0.5% to about 20% by weight, of the carboxylic acid component other than undecylenic acid
-from about 2% to about 55% by weight, preferably from about 5% to about 55% by weight, more preferably from about 10% to about 30% by weight, of the monohydric alcohol, and - from 0 to about 25% by weight, preferably from about 1 % to about 15% by weight, of the urea based component.
Although the preferred urea-based component is urea itself, a suitable urea-based component can comprise urea peroxide or carbamide peroxide. Urea-based components act as nail penetrators and/or softeners. Further, these urea-based components serve a cosmetic function in that they improve the visual appearance of the nail by hydrating and thinning hyperkeratotic nails, thereby providing an incentive for the user to be diligent in applying the DAC.
In addition to the urea-based component, the carrier of the present invention comprises a monohydric alcohol containing 2 to 4 carbon atoms. The monohydric alcohol can be ethanol, propanol, isopropanol, etc., isopropanol being preferred. Optionally, the carrier can contain up to about 7% water.
The carrier of the present invention also contains a carboxylic acid component other than undecylenic acid. Generally speaking, the carboxylic acid component comprises a C1 to C10 organic acid which can be alone and/or in an aqueous solution. Non-limiting examples of C1 -C10 carboxylic acids suitable for use in the carrier of the present invention include saturated and/or unsaturated, linear and/or branched, aliphatic, mono-, di-, carboxylic acids, alkylaryl or aromatic dicarboxylic acids, oxy- and hydroxyl- carboxylic acids (e.g., alpha- hydroxy acids). Preferred carboxylic acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, capyric acid, capric acid, sorbic acid, oxalic acid, hydroxybutyric acid, hydroxypropionic acids, lactic acid, glycolic acid, citric acid, malic acid, tartartic acid, malonic acid, fumaric acid, succinic acid, glutaric acid, apidic acid, pimelic acid, oxalacetic acid, phthalic acid, tartronic acid, pyruvic acid, and mixtures thereof. An especially preferred carboxylic acid is lactic acid.
One of the primary ingredients used in the carrier of the present invention is undecylenic acid (undec-10-enoic acid), an unsaturated fatty acid. While not wanting to be bound by any particular theory, it is believed undecylenic acid acts as a linking agent which brings certain components of the carrier together to enhance penetration. It is also believed that undecylenic acid can act as a biocide/antimicrobial to some extent and thereby enhance the stability of the carrier of the present invention. Further, when the carrier is used in forming a DAC employing an antifungal as the active ingredient, the undecylenic acid has the additional benefit that, in and of itself, in certain amounts it possesses antifungal properties thereby enhancing the efficacy of the DAC. Undecylenic acid also reduces the surface tension of and emulsifies other agents present in the carrier.
An important ingredient in the carrier of the present invention is dimethyl isosorbide (DMI).
A useful component which can be used in the carrier of the present invention can also include a diol containing from about 2 to about 4 carbon atoms. Non-limiting examples of suitable diols include ethylene glycol, propylene glycol, etc. A preferred diol is propylene glycol. If used, the diol will generally be present in an amount of from about 4 to about 15% by weight, preferably from about 4 to about 10% by weight.
Another useful component which can be used in the carrier comprises about 10% by weight of a carboxylic acid ester having the formula:
O
!l
R1-C-O-R2 I
wherein Ri comprises 1 to 3 carbon atoms, and R2 comprises 2 to 4 carbon atoms.
Yet another useful component which may be used in the carrier comprises from about 2 to about 10% by weight of a fatty acid ester having the formula
Figure imgf000009_0001
II
wherein Ri comprises 1 to 3 carbon atoms, R3 comprises 10 to 22 carbon atoms.
The adjunct components mentioned above, i.e. , diols and esters, including the fatty acid esters, can be useful in certain applications to make the DACs more pleasing in smell and/or for ease in application. However, they are not considered to be critical components of the carrier and/or the DACs comprising the carrier.
A feature of the carrier of the present invention is that a wide variety of DAI’s are dispersible in the carrier. In this regard the term “dispersible,” “dispersion,” or variants thereof is intended to mean and include a solution, an emulsion, a suspension, or a slurry to the extent the slurry can be formed into a uniform dispersion of particles / carrier with sufficient agitation and remain in that uniform state for a period of time sufficient for the carrier and its dispersed ingredient(s) to be uniformly applied to a skin surface, e.g., the nail and surrounding tissue.
As used herein “dermatologically active ingredient” (DAI) includes cosmetic and/or pharmaceutical components or compounds which, when applied to skin tissue, provide an aesthetic and/or curative effect. As noted, the carrier of the present invention is a liquid vehicle in which the DAI can be dissolved, suspended, dispersed, or emulsified. Thus, the DAC of the present invention, may form a single phase, e.g., a solution, or separate phases, e.g., a slurry, emulsion, suspension, or the like. In any event, when the constituents, e.g., the DAI forms a separate phase, as in a slurry, the slurry will be one which upon sufficient agitation can be formed into a uniform dispersion or suspension for a period of time to allow the DAC to be applied to the desired skin or nail area, the DAI being delivered to the affected skin area in a generally uniform fashion. The DAC of the present invention may be prepared in a number of forms including creams, milks, solutions, tinctures, liniments, liquids, sprays, suspensions, gels, or lotions.
In respect of DAIs which are cosmetic in nature, it should be noted that the carrier composition of the present invention can be used to “bleach” and/or remove discoloration from nails which may have been caused by several well known underlying diseases. Thus, the DAC, from a cosmetic perspective, can be the carrier alone or have incorporated the DAIs such as skin softeners, emollients, etc.
With particular reference to the DAI comprising an antifungal, virtually any antifungal can be employed. For example, the following well known, widely used antifungals for skin tissue, including nails, includes, without limitation:
-Azoles, including efinaconazole, clotrimazole, miconazole nitrate, ketoconazole, econazole, bifonazole, oxiconazole, tioconazole, sertaconazole, luliconazole, eberconazole, sulconazole, fenticonazole, fluconazole, preferably efinaconazole, clotrimazole, or miconazole nitrate.
-Allylamines, including preferably, terbinafine, naftifine hydrochloride, butenafine hydrochloride,
-Morpholines, including preferably amorolfine hydrochloride
Hydroxyquinolines, including preferably clioquinol
-Oxaboroles, including preferably tavaborole
-Thiocarbamates, including preferably tolfnaftate
-Iodines, including povidone iodine -Pyridones, including preferably ciclopirox
In a more preferred embodiment, the antifungal is selected from thiocarbamates, azoles, and allylamines, even more preferably tolnaftate, clotrimazole, and terbinafine, the most preferred antifungal being tolnaftate.
The above listed antifungals will be incorporated into the carrier forming one of the various types of dispersions noted above.
In general, when antifungals comprise the DAI, they will be present in an effective amount, wherein an effective amount means an amount necessary to affect a curative change in the fungus or other abnormality being treated. In this regard, it is well within the scope of the skilled artisan to determine what constitutes an effective amount. The literature is replete with compositions containing antifungals and the relative amounts used in such compositions. Accordingly, the skilled artisan would not have to engage in undue experimentation to determine what amount of antifungal should be used in the DACs of the present invention. As a general rule, when the antifungals comprise the DAI, they will comprise from greater than 0 to about 15% by weight or greater of the DAC.
To demonstrate the penetrating ability of the carrier composition and DACs made therefrom, a series of tests were performed as follows:
A) The antifungal component was mixed with dimethyl isosorbide, forming
Mixture A. B) Urea, undecylenic acid, lactic acid, and IPA were mixed together forming Mixture B.
C) Mixture A and Mixture B were combined.* *The tolfnaftate sample was made in an earlier batch and was made as follows:
D) Tolnaftate was mixed with DMI and then undecylenic acid was added, forming Mixture D.
E) Urea, lactic acid and IPA were mixed together, forming Mixture E.
F) Mixture D and Mixture E were combined.
The compositions of the various DACs prepared are shown in Table 1.
TABLE 1
Figure imgf000013_0001
1. Uniformly dispersible on shaking. To demonstrate penetrating ability of the carrier and more specifically DACs prepared using the carrier of the present invention, the samples were tested against a commercial product sold under the name Jublia®. The antifungal in the Jublia® composition is efinaconazole and the vehicle is isopropanol as well as a surfactant and a volatile siloxane.
The penetration test was conducted using a substrate comprising polyurethane foam blocks marketed by Pacific Research Laboratories under the designation“Block 10 PCF” and commonly used for biomechanical testing. The faces of two blocks of the substrate were positioned between platens, the assembly of platens and substrate blocks being compressed together using the same and constant compression for each test.. Each of the samples was dyed with fluorescein to improve visibility of the liquid. Two drops of each sample were applied at the top on the seam between the compressed substrate blocks. The samples were allowed to sit for 20 seconds, then the excess liquid was dabbed away. The samples were then allowed to dry for 2 minutes, after which the blocks were separated. The amount of penetration of the sample through the substrate was observed. As can be seen in Fig. 1 , the borders of the penetration of the samples have been traced with a marker for ease of viewing. As can be seen, all of the compositions of the present invention penetrated further than the Jublia® composition.
As can be seen from the above results, the carrier compositions of the present invention are effective at dispersing, as that term is defined above, a wide variety of antifungals from varied classes of antifungals, all of which are known to have antifungal activity. Further, and importantly, when compared with the widely used Jublia® antifungal composition containing a lower alcohol such as isopropanol, the DACs of the present invention wherein the DAIs are antifungals show better penetrating ability than the Jublia® formulation. This is significant, as noted above, since in the Jublia® composition in order to enhance penetration, the compositions require, in addition to an alcohol, a surfactant, and a volatile silicone wetting agent. Importantly, unlike the Jublia® composition, the preferred embodiment of the present composition incorporates urea and lactic acid which collectively thin thickened nails, enhance nail hydration and diminish discoloration.
Although specific embodiments of the invention have been described herein in some detail, this has been done solely for the purposes of explaining the various aspects of the invention, and is not intended to limit the scope of the invention as defined in the claims which follow. Those skilled in the art will understand that the embodiment shown and described is exemplary, and various other substitutions, alterations and modifications, including but not limited to those design alternatives specifically discussed herein, may be made in the practice of the invention without departing from its scope.

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutically active composition for application to nails and surrounding tissue, comprising:
an effective amount of a pharmacologically active antifungal component; and
a carrier, said carrier comprising:
from greater than 0 to about 40% by weight of dimethyl isosorbide; from about 1 to about 40% by weight of undecylenic acid;
from greater than 0 to about 30% by weight of a carboxylic acid component other than undecylenic acid;
from about 2 to about 55% by weight of a monohydric alcohol having from 2 to 4 carbon atoms;
from greater than 0 to about 25% by weight of a urea based component, said antifungal component being uniformly dispersible in said carrier.
2. The composition of claim 1 , wherein said composition comprises: from greater than 0 to about 15% by weight of said antifungal component from about 1 to about 20% by weight of said dimethyl isosorbide;
from about 5 to about 35% by weight of said undecylenic acid;
from about 0.5 to about 20% by weight of said carboxylic acid component other than undecylenic acid; from about 10 to about 30% by weight of said monohydric alcohol having from 2 to 4 carbon atoms;
from about 1 to about 15% by weight of said urea based component.
3. The composition of claim 1 , further comprising from about 2 to about 10% by weight of a carboxylic acid ester having the formula:
O
R1-C-0-R2
I
wherein Ri comprises 1 to 3 carbon atoms, and R2 comprises 2 to 4 carbon atoms.
4. The composition of claim 1 , further comprising:
from about 2 to about 10% by weight of a fatty acid ester having the formula
Figure imgf000017_0001
II
wherein Ri comprises 1 to 3 carbon atoms, R3 comprises 10 to 22 carbon atoms.
5. The composition of claim 1 , wherein said urea-based component comprises urea.
6. The composition of claim 1 , wherein said monohydric alcohol comprises isopropyl alcohol.
7. The composition of claim 1 , wherein said carboxylic acid component is selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, capyric acid, capric acid, sorbic acid, oxalic acid, hydroxybutyric acid, hydroxypropionic acids, lactic acid, glycolic acid, citric acid, malic acid, tartaric acid, malonic acid, fumaric acid, succinic acid, glutaric acid, apidic acid, pimelic acid, oxalacetic acid, phthalic acid, tartronic acid, pyruvic acid, and mixtures thereof.
8. The composition of claim 7, wherein said carboxylic acid comprises lactic acid.
9. The composition of claim 4, wherein said fatty acid ester comprises isopropyl myristate in an amount of from about 2 to about 10% by weight.
10. The composition of claim 1 , further comprising from about 4 to about 10% by weight of a diol containing from 2 to 4 carbon atoms.
11. A carrier for use in topical application of dermatologically active ingredients, comprising:
from greater than 0 to about 40% by weight of dimethyl isosorbide;
from about 1 to about 40% by weight of undecylenic acid;
from greater than 0 to about 30% by weight of a carboxylic acid component other than undecylenic acid;
from about 2 to about 55% by weight of a monohydric alcohol having from 2 to 4 carbon atoms;
from greater than 0 to about 25% by weight of a urea based component.
12. The carrier of claim 11 , comprising:
from about 1 to about 15% by weight of said dimethyl isosorbide;
from about 5 to about 25% by weight of said undecylenic acid;
from about 0.5 to about 10% by weight of said carboxylic acid component other than undecylenic acid;
from about 10 to about 30% by weight of said monohydric alcohol having from 2 to 4 carbon atoms; and
from about 1 to about 15% by weight of said urea based component.
13. The composition of claim 11 , further comprising from about 2 to about 10% by weight of a carboxylic acid ester having the formula:
Figure imgf000020_0001
I
wherein Ri comprises 1 to 3 carbon atoms, and R2 comprises 2 to 4 carbon atoms.
14. The composition of claim 11 , further comprising:
from about 2 to about 10% by weight of a fatty acid ester having the formula o
R1-C-0-R3
II
wherein Ri comprises 1 to 3 carbon atoms, R3 comprises 10 to 22 carbon atoms.
15. The composition of claim 11 , wherein said urea-based component comprises urea.
16. The composition of claim 11 , wherein said monohydric alcohol comprises isopropyl alcohol.
17. The composition of claim 11 , wherein said carboxylic acid component is selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, capyric acid, capric acid, sorbic acid, oxalic acid, hydroxybutyric acid, hydroxypropionic acids, lactic acid, glycolic acid, citric acid, malic acid, tartaric acid, malonic acid, fumaric acid, succinic acid, glutaric acid, apidic acid, pimelic acid, oxalacetic acid, phthalic acid, tartronic acid, pyruvic acid, and mixtures thereof.
18. The composition of claim 17, wherein said carboxylic acid comprises lactic acid.
19. The composition of claim 14, wherein said fatty acid ester comprises isopropyl myristate in an amount of from about 2 to about 10% by weight.
20. The composition of claim 11 , further comprising from about 4 to about 10% by weight of a diol containing from 2 to 4 carbon atoms.
PCT/US2019/023203 2018-12-19 2019-03-20 Topical compositions WO2020131147A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3122016A CA3122016A1 (en) 2018-12-19 2019-03-20 Topical compositions
JP2021536333A JP2022518357A (en) 2018-12-19 2019-03-20 Local composition
AU2019405915A AU2019405915A1 (en) 2018-12-19 2019-03-20 Topical compositions
EP19898484.1A EP3897604A4 (en) 2018-12-19 2019-03-20 Topical compositions
SG11202105755PA SG11202105755PA (en) 2018-12-19 2019-03-20 Topical compositions
KR1020217022200A KR20210107043A (en) 2018-12-19 2019-03-20 topical composition
MX2021006810A MX2021006810A (en) 2018-12-19 2019-03-20 Topical compositions.
IL284072A IL284072A (en) 2018-12-19 2021-06-16 Topical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/225,980 US10543276B2 (en) 2016-08-08 2018-12-19 Topical compositions
US16/225,980 2018-12-19

Publications (1)

Publication Number Publication Date
WO2020131147A1 true WO2020131147A1 (en) 2020-06-25

Family

ID=71102691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/023203 WO2020131147A1 (en) 2018-12-19 2019-03-20 Topical compositions

Country Status (9)

Country Link
EP (1) EP3897604A4 (en)
JP (1) JP2022518357A (en)
KR (1) KR20210107043A (en)
AU (1) AU2019405915A1 (en)
CA (1) CA3122016A1 (en)
IL (1) IL284072A (en)
MX (1) MX2021006810A (en)
SG (1) SG11202105755PA (en)
WO (1) WO2020131147A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455592B1 (en) * 1991-03-08 2002-09-24 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20060165747A1 (en) * 2005-01-24 2006-07-27 David Rolf Antifungal composition, method and kit for topically treating onychomycosis
US20080299220A1 (en) * 2003-08-04 2008-12-04 Dov Tamarkin Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US10206962B1 (en) * 2016-08-08 2019-02-19 Marlinz Pharma, LLC Method for treating fungal infections in nails

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921529B2 (en) * 2002-07-29 2005-07-26 Joseph C. Maley Treatment modality and method for fungal nail infection
WO2009048841A1 (en) * 2007-10-09 2009-04-16 Humco Holding Group, Inc. Antifungal treatment of nails
BR112012003209A2 (en) * 2009-08-13 2016-03-01 Moberg Derma Ab compositions and methods for treating fungal nail infection
GB2478159A (en) * 2010-02-26 2011-08-31 Lrc Products Composition for the treatment of fungal nail infection
WO2014140507A1 (en) * 2013-03-15 2014-09-18 Moberg Pharma Ab Pharmaceutical composition for the treatment of fungal infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455592B1 (en) * 1991-03-08 2002-09-24 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20080299220A1 (en) * 2003-08-04 2008-12-04 Dov Tamarkin Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20060165747A1 (en) * 2005-01-24 2006-07-27 David Rolf Antifungal composition, method and kit for topically treating onychomycosis
US10206962B1 (en) * 2016-08-08 2019-02-19 Marlinz Pharma, LLC Method for treating fungal infections in nails

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3897604A4 *

Also Published As

Publication number Publication date
AU2019405915A1 (en) 2021-06-24
KR20210107043A (en) 2021-08-31
MX2021006810A (en) 2021-07-02
EP3897604A1 (en) 2021-10-27
IL284072A (en) 2021-08-31
EP3897604A4 (en) 2022-08-17
JP2022518357A (en) 2022-03-15
CA3122016A1 (en) 2020-06-25
SG11202105755PA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
AU2002246119B2 (en) Topical composition
US8840911B2 (en) Moisturizing hand sanitizer
JP4166689B2 (en) Use of 1,2-decanediol against bacteria causing body odor
AU2002246119A1 (en) Topical composition
CN108771637A (en) Act synergistically ternary antimicrobial mixtures
KR20080080355A (en) Pharmaceutical composition for application to nail
JP2008517037A (en) Synergistic mixture comprising 1,2-hexanediol and 1,2-octanediol and further a preservative
JP2013503123A (en) Use of 1,3-diols as biocides
HUE035285T2 (en) Composition for topical application, uses thereof, applicator device and kit of parts
WO2005016328A1 (en) Topical compositions of urea
HUE026887T2 (en) New pharmaceutical composition for the treatment of fungal infections
US10543276B2 (en) Topical compositions
JP2020059758A (en) Stabilized multiple emulsions as skin protection products
JP2004352688A (en) Antiseptic agent
JPS6355483B2 (en)
RU2006133386A (en) SKIN CARE COMPOSITIONS CONTAINING SALICYLIC ACID
WO2020131147A1 (en) Topical compositions
CN107427006A (en) Isobide ether derivant with antiseptic activity
US9775346B1 (en) Hand sanitizer composition and method of manufacture
CN106470677A (en) For treating the constituent of dermatological disease and disease
CA2998895A1 (en) Topical antifungal compositions
JP2007501832A (en) Topical composition containing terbinafine and hydrocortisone
JP2007501832A6 (en) Topical composition containing terbinafine and hydrocortisone
JP4926354B2 (en) Topical skin preparation
US20210274780A1 (en) Disinfectant Composition Against the Novel Wuhan Corona Virus COVID-19

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19898484

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3122016

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021536333

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019405915

Country of ref document: AU

Date of ref document: 20190320

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217022200

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019898484

Country of ref document: EP

Effective date: 20210719